For example, [18F]F13640 shows high binding values in the raphe, consistent with the therapeutic-like activity of 5-HT1A receptor agonists in rodent and non-human primate models of L-DOPA-induced dyskinesia (LID) in Parkinson’s disease [50–52] which is the focus of an ongoing clinical study (ClinicalTrials.gov Identifier: NCT05148884). Here, HTR1A is linked to drug-induced dyskinesia.